Dyadic International (DYAI) investor relations material

Strategic transition and business model evolution

• Transitioned from R&D to commercial focus, rebranding and launching products in life sciences, food, nutrition, and bioindustrial sectors.

• Developed two platforms, C1 for complex proteins and Dapibus for simpler, high-volume proteins, enabling entry into multiple markets.

• Revenue strategy centers on direct product sales, licensing, and third-party funded projects, prioritizing near-term, non-therapeutic products.

• Shifted focus from licensing technology to generating revenue through product commercialization and strategic partnerships.

• Embedded CRISPR technology to accelerate strain optimization and expand into new product categories, especially molecular biology reagents.

Product launches and commercial traction

• Launched key products including DNase I, human albumin, and growth factors, with additional launches like transferrin and alpha-lactalbumin planned for 2026–2027.

• Partners such as Proliant Health & Biologicals and Inzymes have launched products, generating milestone and license fees exceeding $2.9 million.

• Expanded manufacturing capabilities through Fermbox Bio, enabling inventory build-up and broader market reach.

• Entered food and nutrition markets with non-animal dairy proteins and enzymes, securing partnerships and initial bulk orders.

• Bioindustrial segment focused on cellulosic enzymes, with first bulk orders and product launches like EN3ZYME and expansion into Asia-Pacific.

Revenue outlook and growth drivers

• Revenue base built on direct product sales, with additional layers from licensing and partnership agreements.

• Expecting revenue inflection from late 2026 as more products and partnerships mature, aiming for a steady run rate.

• Strategic collaborations and distribution agreements targeted to accelerate market penetration and revenue growth.

• Legacy R&D programs in human and animal therapeutics remain fully funded and may provide long-term momentum without draining resources.

• Near-term revenues are focused on non-therapeutic products that bypass lengthy regulatory processes, enabling faster commercialization.